WO2011141929A3 - Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine - Google Patents

Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine Download PDF

Info

Publication number
WO2011141929A3
WO2011141929A3 PCT/IN2011/000324 IN2011000324W WO2011141929A3 WO 2011141929 A3 WO2011141929 A3 WO 2011141929A3 IN 2011000324 W IN2011000324 W IN 2011000324W WO 2011141929 A3 WO2011141929 A3 WO 2011141929A3
Authority
WO
WIPO (PCT)
Prior art keywords
olopatadine
fluticasone
pharmaceutical compositions
aqueous pharmaceutical
relates
Prior art date
Application number
PCT/IN2011/000324
Other languages
English (en)
Other versions
WO2011141929A2 (fr
Inventor
Sunilendu Bhushan Roy
Kapileswar Swain
Shailesh Arvindbhai Patel
Laxman Magar
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Publication of WO2011141929A2 publication Critical patent/WO2011141929A2/fr
Publication of WO2011141929A3 publication Critical patent/WO2011141929A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des solutions de pulvérisation nasale aqueuses de fluticasone et d'olopatadine. La présente invention concerne en particulier une solution de pulvérisation nasale aqueuse stable qui comprend une combinaison de fluticasone et d'olopatadine ou de sels acceptables sur le plan pharmaceutique de ceux-ci ainsi qu'un procédé de fabrication associé. La composition aqueuse est particulièrement adaptée à une administration topique dans le nez pour le traitement d'états inflammatoires.
PCT/IN2011/000324 2010-05-11 2011-05-10 Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine WO2011141929A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1487MU2010 2010-05-11
IN1487/MUM/2010 2010-05-11

Publications (2)

Publication Number Publication Date
WO2011141929A2 WO2011141929A2 (fr) 2011-11-17
WO2011141929A3 true WO2011141929A3 (fr) 2012-03-22

Family

ID=44629755

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000324 WO2011141929A2 (fr) 2010-05-11 2011-05-10 Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine

Country Status (1)

Country Link
WO (1) WO2011141929A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112656882B (zh) * 2021-01-29 2021-12-10 衡水以岭药业有限公司 一种妇血安薄膜包衣片及其制备方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
MX367674B (es) 2013-09-13 2019-08-30 Glenmark Specialty Sa Composición farmacéutica de dosis fija estable que comprende mometasona y olopatadina.
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
UA120587C2 (uk) 2013-10-04 2020-01-10 Гленмарк Спешіалті С.А. Спосіб лікування алергічного риніту з використанням комбінації мометазону та олопатадину
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN106256351A (zh) * 2015-06-18 2016-12-28 江苏吉贝尔药业股份有限公司 盐酸奥洛他定凝胶滴眼液及其制备方法
MX2020008741A (es) 2018-02-23 2020-09-28 Glenmark Specialty Sa Tratamiento de la rinitis alergica en sujetos pediatricos con una combinacion de mometasona y olopatadina.
CN114980881A (zh) * 2019-12-06 2022-08-30 东兴药品工业株式会社 包含奥洛他定的鼻用组合物
TW202133860A (zh) * 2019-12-06 2021-09-16 日商東興藥品工業股份有限公司 含有類固醇化合物及歐羅派特錠的醫藥組成物
AU2021291684A1 (en) * 2020-06-15 2022-12-08 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
US12016941B2 (en) * 2022-03-03 2024-06-25 Profounda Health And Beauty Inc. Treatment composition for nasal and oral dryness, nosebleeds, and allergy symptoms
CN118557530B (zh) * 2024-08-02 2024-10-11 北京爱力佳医药科技有限公司 一种含盐酸奥洛他定儿童药物组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043470A1 (fr) * 2002-11-12 2004-05-27 Alcon, Inc. Utilisation d'un agent anti-allergique et d'un steroide pour traiter une rhinite allergique
US20060110331A1 (en) * 2004-11-24 2006-05-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
WO2009003199A1 (fr) * 2007-06-28 2008-12-31 Cydex Pharmaceuticals, Inc. Administration nasale et ophtalmique de solutions aqueuses de corticostéroïdes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1201114A (fr) 1980-02-15 1986-02-25 Gordon H. Phillipps Carbothioates d'androstane
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
WO1997001337A1 (fr) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. Combinaison d'antihistamines et de steroides a application topique par voie nasale
EP0780127A1 (fr) 1995-12-19 1997-06-25 The Procter & Gamble Company Pulvérisateur nasale contenant un stéréoide et un antihistamine
AU7859800A (en) 1999-10-08 2001-04-23 Schering Corporation Topical nasal treatment
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20090136430A1 (en) 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043470A1 (fr) * 2002-11-12 2004-05-27 Alcon, Inc. Utilisation d'un agent anti-allergique et d'un steroide pour traiter une rhinite allergique
US20060110331A1 (en) * 2004-11-24 2006-05-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
WO2009003199A1 (fr) * 2007-06-28 2008-12-31 Cydex Pharmaceuticals, Inc. Administration nasale et ophtalmique de solutions aqueuses de corticostéroïdes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112656882B (zh) * 2021-01-29 2021-12-10 衡水以岭药业有限公司 一种妇血安薄膜包衣片及其制备方法

Also Published As

Publication number Publication date
WO2011141929A2 (fr) 2011-11-17

Similar Documents

Publication Publication Date Title
WO2011141929A3 (fr) Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine
WO2013101897A3 (fr) Compositions et procédés d'administration d'oméprazole plus acide acétylsalicylique améliorés
WO2010088000A3 (fr) Composés antifibrotiques et leurs utilisations
WO2012076466A3 (fr) Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
WO2013021199A3 (fr) Compositions pharmaceutiques
WO2009109618A3 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1, cx3cr1 et p40
WO2011158039A8 (fr) Dérivés d'uréido-pyrazole destinés à être utilisés dans le traitement d'infections par un rhinovirus
WO2012116290A3 (fr) Stéroïdes neuroactifs substitués par 17(20)-z-vinylcyano, promédicaments de ceux-ci et procédés de traitement les utilisant
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
WO2011012816A3 (fr) Formulation pharmaceutique
WO2013147649A3 (fr) Inhibiteurs de la voie de signalisation pi3k/akt/ikk/nf-kb, leurs sels pharmaceutiquement acceptables et compositions les comprenant pour la prévention et le traitement de maladies virales
WO2009109616A8 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l'expression de mcp-1, cx3cr1 et p40
WO2014016548A3 (fr) Composition pharmaceutique
WO2012016845A3 (fr) Formulation pharmaceutique comprenant un inhibiteur de phosphodiestérase
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
WO2013022243A3 (fr) Nouveau dérivé biphénylé ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique pour prévenir ou traiter les maladies inflammatoires ou les maladies auto-immunes comprenant ce dérivé ou ce sel comme principe actif
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
WO2009109654A8 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1 et cx3cr1
WO2010090494A3 (fr) Utilisation médicale de dérivés d'acide 5-benzylaminosalicylique ou de sels correspondants
EP2796450A4 (fr) Dérivés 6-aminopyridine-3-ol ou leurs sels pharmaceutiquement acceptables, et composition pharmaceutique contenant ces dérivés ou ces sels comme principes actifs pour la prévention ou le traitement des maladies provoquées par l'angiogenèse
WO2012162439A3 (fr) Compositions comprenant de l'acide fusidique et leurs emballages
JP2013515022A5 (fr)
WO2011037976A3 (fr) Formulations pharmaceutiques de pramipexole
BR112015026053A2 (pt) composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratamento de um paciente sofrendo ou susceptível a sofrer de um distúrbio respiratório e para fabricação de uma composição farmacêutica
WO2011093818A3 (fr) Compositions pharmaceutiques comprenant du salmétérol et du fluticasone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11740988

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11740988

Country of ref document: EP

Kind code of ref document: A2